ArticleImmuno-oncology technology2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

N Alshatti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.